Why is AbbVie considered a buyout target?

Due to its large size, strong product portfolio, and growth potential, making it attractive to larger companies.

2 Biotech Stocks Worth Buying Before Their Potential Buyouts

Q: Is it guaranteed that these stocks will be acquired?

No, buyout deals are not guaranteed and may be affected by regulatory or pricing factors.

The biotech sector is experiencing a banner year for buyouts. This article highlights two companies, including AbbVie, that are considered prime acquisition targets.

June 27, 2026

2 min read

Source: Motley Fool

According to a report by Motley Fool, the biotech sector is having a record year for acquisitions, with two prominent companies believed to be strong candidates for buyout deals.

Details

The report did not explicitly name both companies but indicated that one of them is AbbVie (ticker: ABBV). AbbVie operates in pharmaceuticals and biotechnology, known for drugs like Humira and Skyrizi. Its large size and strong product portfolio make it an attractive acquisition target.

Context

These predictions come amid a wave of record acquisitions in the sector this year, as large companies seek to strengthen their pipelines by acquiring innovative firms. The report did not specify the second company but noted it is another sector player with promising growth potential.

What It Means for Investors

These forecasts suggest that investors may see acquisition premiums on these stocks if deals materialize. However, investors should remain cautious, as buyout deals are not guaranteed and may be affected by regulatory or pricing factors.

Frequently Asked Questions

AbbVie is an American pharmaceutical and biotechnology company, known for drugs like Humira and Skyrizi.

Found this useful? Share it

This article was rewritten in Wrqti's editorial style based on information from the original source above. Content is informational only — not investment advice.